| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 23073 |
| Drug | Tremelimumab |
| Brand | Imjudo® |
| Indication | Tremelimumab (Imjudo®) in combination with durvalumab (Imfinzi®) is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma. |
| Assessment Process | |
| Rapid review commissioned | 06/12/2023 |
| Rapid review completed | 11/01/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tremelimumab in combination with durvalumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 01/02/2024 |
| Pre-submission consultation with Applicant | 26/03/2024 |
| Full submission received from Applicant | 16/07/2024 |
| Preliminary review sent to Applicant | 20/03/2025 |
| NCPE assessment re-commenced | 24/04/2025 |
| Follow-up to preliminary review sent to Applicant | 02/05/2025 |
| NCPE assessment re-commenced | 08/05/2025 |
| Factual accuracy sent to Applicant | 06/06/2025 |
| NCPE assessment re-commenced | 13/06/2025 |
| NCPE assessment completed | 11/07/2025 |
| NCPE assessment outcome | The NCPE recommends that tremelimumab in combination with durvalumab (STRIDE) not be considered for reimbursement*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.